Recombinant Malaria Vaccine
A special issue of Vaccines (ISSN 2076-393X).
Deadline for manuscript submissions: closed (31 October 2016) | Viewed by 144
Special Issue Editor
Special Issue Information
Dear Colleagues,
Despite substantial progress in malaria control, millions of people, particularly in Africa, remain at risk of disease and death. Vaccines are viewed as one of the most promising medical intervention especially in terms of health care costs, however, poor immune response together with the parasite’s complex strategy to evade the host immune system makes vaccine development very difficult. Up to now no vaccine for malaria has been licensed. A number of malaria vaccine candidates are at either advance preclinical or clinical stages of evaluation. This special issue aims to cover various efforts of the malaria research community to come up with safe and effective recombinant vaccines: the innovative technologies for post-genome malaria vaccine candidate discovery, evaluation of vaccine candidates, host immune reaction to the vaccine and programmatic issues that can be encountered for vaccine impact and safety before licensure.
Prof. Dr. Toshihiro Horii
Guest Editor
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Recombinant malaria vaccines
- Plasmodium falciparum
- Plasmodium vivax
- Vaccine adjuvants
- Immunology
